Abstract:Mutations in activin-like kinase 2 (ALK2), e.g., ALK2-R206H, induce aberrant signaling to SMAD1/5/8, leading to Fibrodysplasia Ossificans Progressiva (FOP). In spite of extensive studies, the underlying mechanism is still unclear. Here, we quantified the homomeric and heteromeric interactions of ACVR2A, ACVR2B, ALK2-WT, and ALK2-R206H by combining IgG-mediated immobilization of one receptor with fluorescence recovery after photobleaching (FRAP) measurements on the lateral diffusion of a co-expressed receptor. ACVR2B formed stable homomeric complexes that were enhanced by Activin A (ActA), while ACVR2A required ActA for homodimerization. ALK2-WT, but not ALK2-R206H, exhibited homomeric complexes unaffected by ActA. ACVR2B formed ActA-enhanced heterocomplexes with ALK2-R206H or ALK2-WT, while ACVR2A interacted mainly with ALK2-WT. The extent of the homomeric complex formation of ACVR2A or ACVR2B was reflected in their ability to induce the oligomerization of ALK2-R206H and ALK2-WT. Thus, ACVR2B, which forms dimers without ligand, induced ActA-independent ALK2-R206H clustering but required ActA for enhancing the oligomerization of the largely dimeric ALK2-WT. In contrast, ACVR2A, which undergoes homodimerization in response to ActA, required ActA to induce ALK2-R206H oligomerization. To investigate whether these interactions are translated into signaling, we studied signaling by the FOP-inducing hyperactive ALK2-R206H mutant, with ALK2-WT signaling as control. The activation of SMAD1/5/8 signaling in cells expressing ALK2-R206H alone or together with ACVR2A or ACVR2B was measured by blotting for pSMAD1/5/8 and by transcriptional activation assays using BRE-Luc reporter. In line with the biophysical studies, ACVR2B activated ALK2-R206H without ligand, while activation by ACVR2A was weaker and required ActA. We propose that the homodimerization of ACVR2B or ACVR2A dictates their ability to recruit ALK2-R206H into higher complexes, enabling the homomeric interactions of ALK2-R206H receptors and, subsequently, their activation.

Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling

Tgf-Beta and Bmp Signaling in Osteoblast, Skeletal Development, and Bone Formation, Homeostasis and Disease

Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B

Activins as Dual Specificity TGF-β Family Molecules: SMAD-Activation via Activin- and BMP-Type 1 Receptors

Coordinate regulation of Activin and Bone Morphogenetic Protein signaling by a lysosomal trafficking switch

Promiscuous signaling of ligands via mutant ALK2 in fibrodysplasia ossificans progressiva

The Biological Function of Type I Receptors of Bone Morphogenetic Protein in Bone

Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms

Bone Morphogenetic Protein Receptors: Structure, Function and Targeting by Selective Small Molecule Kinase Inhibitors

The Activation of the Fibrodysplasia Ossificans Progressiva-Inducing ALK2-R206H Mutant Depends on the Distinct Homo-Oligomerization Patterns of ACVR2B and ACVR2A

Measurement of Constitutive Activity of BMP Type I Receptors

Phosphorylation regulation of the interaction between Smad7 and activin type I receptor.

Functional Antagonism Between Activin And Osteogenic Protein-1 In Human Embryonal Carcinoma Cells

Alk2 R206h Mutation Linked to Fibrodysplasia Ossificans Progressiva Confers Constitutive Activity to the Bmp Type I Receptor and Sensitizes Mesenchymal Cells to Bmp-Induced Osteoblast Differentiation and Bone Formation

Divergent activities of osteogenic BMP2, and tenogenic BMP12 and BMP13 independent of receptor binding affinities

Identification of Type I Receptors for Osteogenic Protein-1 and Bone Morphogenetic Protein-4.

Signal Transduction: Gain of Activin Turns Muscle into Bone

BMP-9 Signals Via ALK1 and Inhibits Bfgf-Induced Endothelial Cell Proliferation and VEGF-stimulated Angiogenesis

Biphasic effects of transforming growth factor β on bone morphogenetic protein-induced osteoblast differentiation

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva

Antisense-oligonucleotide Mediated Exon Skipping in Activin-Receptor-like Kinase 2: Inhibiting the Receptor That is Overactive in Fibrodysplasia Ossificans Progressiva.